These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 7703567)
1. [Amplification of c-myc and c-erbbeta-2(HER-2/neu) in breast cancer without axillary lymph node metastasis: correlation with other prognostic parameters]. Lizard-Nacol S; Arnould L; Riedinger JM; Arnal M; Collin F; Guerrin J Bull Cancer; 1994 Sep; 81(9):780-4. PubMed ID: 7703567 [TBL] [Abstract][Full Text] [Related]
2. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370 [TBL] [Abstract][Full Text] [Related]
3. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients. Scorilas A; Yotis J; Gouriotis D; Keramopoulos A; Ampela K; Trangas T; Talieri M Anticancer Res; 1993; 13(5C):1895-900. PubMed ID: 7903524 [TBL] [Abstract][Full Text] [Related]
4. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer. Champème MH; Bièche I; Hacène K; Lidereau R Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157 [TBL] [Abstract][Full Text] [Related]
5. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Persons DL; Borelli KA; Hsu PH Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184 [TBL] [Abstract][Full Text] [Related]
6. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Scorilas A; Yotis J; Stravolemos K; Gouriotis D; Keramopoulos A; Ampela K; Talieri M; Trangas T Anticancer Res; 1995; 15(4):1543-7. PubMed ID: 7654043 [TBL] [Abstract][Full Text] [Related]
7. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Tiwari RK; Borgen PI; Wong GY; Cordon-Cardo C; Osborne MP Anticancer Res; 1992; 12(2):419-25. PubMed ID: 1349794 [TBL] [Abstract][Full Text] [Related]
8. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations. Gaffey MJ; Frierson HF; Williams ME Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628 [TBL] [Abstract][Full Text] [Related]
9. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033 [TBL] [Abstract][Full Text] [Related]
11. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P Breast J; 2005; 11(4):278-80. PubMed ID: 15982396 [TBL] [Abstract][Full Text] [Related]
12. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Borg A; Tandon AK; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Killander D; McGuire WL Cancer Res; 1990 Jul; 50(14):4332-7. PubMed ID: 1973070 [TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene. Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174 [TBL] [Abstract][Full Text] [Related]
14. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689 [TBL] [Abstract][Full Text] [Related]
15. c-erbB-2 amplification in node-negative human breast cancer. Ro JS; el-Naggar A; Ro JY; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G Cancer Res; 1989 Dec; 49(24 Pt 1):6941-4. PubMed ID: 2573424 [TBL] [Abstract][Full Text] [Related]
16. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Prati R; Apple SK; He J; Gornbein JA; Chang HR Breast J; 2005; 11(6):433-9. PubMed ID: 16297088 [TBL] [Abstract][Full Text] [Related]
17. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Scorilas A; Trangas T; Yotis J; Pateras C; Talieri M Br J Cancer; 1999 Dec; 81(8):1385-91. PubMed ID: 10604737 [TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728 [TBL] [Abstract][Full Text] [Related]
19. Follow-up study of HER-2/neu amplification in primary breast cancer. Clark GM; McGuire WL Cancer Res; 1991 Feb; 51(3):944-8. PubMed ID: 1988136 [TBL] [Abstract][Full Text] [Related]
20. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Tsuda H; Hirohashi S; Shimosato Y; Hirota T; Tsugane S; Yamamoto H; Miyajima N; Toyoshima K; Yamamoto T; Yokota J Cancer Res; 1989 Jun; 49(11):3104-8. PubMed ID: 2566377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]